Episode 11: Using Real-World Studies to Compare DMTs in MS
Tomas Kalincik, Head of the Clinical Outcomes Research Unit at the University of Melbourne, and Maria Pia Sormani, Professor of Biostatistics at the University of Genoa, discuss the use of real-world data to compare disease-modifying treatments (DMTs) in multiple sclerosis, including the advantages and limitations of randomised control trials and observational studies. Hosted by Alan Thompson, Editor-in-Chief of the MS Journal and Professor at University College London.
If you would like to explore this topic further, please refer to the following MS Journal articles:
- Cohen JA, Trojano M, Mowry EM, et al. Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. Mult Scler 2020;26:23-37
- Kalincik T, Butzkueven H. Observational data: Understanding the real MS world. Mult Scler 2016;22:1642-1648
- Kalincik T, Sormani MP. Reporting treatment outcomes in observational data: A fine balance. Mult Scler 2017;23:21-22.
- Roos I, Diouf I, Sharmin S, et al. Comparative effectiveness in multiple sclerosis: A methodological comparison. Mult Scler 2023;29:326-332.